EyePoint, Inc. (EYPT)
EyePoint develops DURAVYU, an investigational sustained release eye treatment for serious retinal diseases. It last closed at $0.30 on Nov 17, down 0.16% on the day. The average 12-month price target from 3 analysts is $3.33 (+1000.5% from the last close), with a high of $5.00 and a low of $1.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From EYPT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on EYPT in the past 90 days. The average target is $3.33, with a high of $5.00 and a low of $1.00, compared with the last close of $0.30.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Stifel | Target lowered | Buy | $40 → $5 |
| Oct 20 | RBC Capital | Target lowered | Hold | $5 → $1 |
| Sep 2 | TD Cowen | Downgrade | Hold | $4 |
| Aug 18 | Citigroup | Maintained | Buy | $17 |
| Aug 18 | RBC Capital | Downgrade | Hold | $5 |
Technical Analysis
The stock is 21% below its 20 day and 612% below its 50 day average. It is 3234% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 18), oversold. The nearest support is the Pivot at $0.30, and the nearest resistance the Pivot R1 at $0.32.
| RSI (14) | 18.15 | Oversold below 30 | Oversold |
| MACD | -0.58 | Above its signal line | Bullish |
| Stochastic | 9.4 | Near the bottom of its range | Oversold |
| ADX (14) | 64.0 | Strong downtrend | |
| Williams %R | -86.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -159.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −24.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.13 | Typical daily range, 42.2% of price |
| RSI (14) | 22.82 | Oversold below 30 | Oversold |
| MACD | -3.29 | Below its signal line | Bearish |
| Stochastic | 0.2 | Near the bottom of its range | Oversold |
| ADX (14) | 37.0 | Trending down | |
| Williams %R | -99.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -83.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −92.8% | Change over 10 sessions | Bearish |
| ATR (14) | $1.36 | Typical daily range, 448.2% of price |
What happened before
See how EYPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How EYPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in EYPT in the last 90 days.
EYPT Institutional Ownership
Full report →- ▲112 buying vs 97 selling
- ▲Held by funds +2.7 pts
- ●Funds holding +0
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 190 | 190 | 0.0% |
| In funds' top 10 | 1 | 7 | −85.7% |
| Held by funds | 84.4% | 81.6% | +2.7 pts |
| New / increased | 44 / 68 | 25 / 65 | +24.4% |
| Reduced / sold out | 54 / 43 | 60 / 24 | +15.5% |
| Put/call ratio | 0.98 | 3.17 | −69.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EYPT is in one of them and how their past EYPT trades turned out.
EYPT News & Analysis
All StreetAlpha news →About EyePoint
EyePoint is a biopharmaceutical company based in Watertown, Massachusetts, that develops treatments for serious retinal diseases of the eye. Its lead candidate, DURAVYU, combines the drug vorolanib with the company's Durasert E drug delivery technology, which is designed to release medicine steadily inside the eye over a long period. The company is testing DURAVYU for wet AMD and diabetic macular edema, and the treatment has not been approved by the FDA. Its intended patients are people with these conditions, and the eye doctors who would treat them.
- Headquarters
- Watertown, MA
- Website
- psivida.com ↗


